Print
Email
Print Edition Stories
MHT's Emerging Technologies Forum: Health IT and the Cloud
Health care industry eyes iPad
Primera Biosystems Inc, a Mansfield-based molecular diagnostics company that does business as PrimeraDx, has appointed Matthew McManus as president and CEO. McManus takes over the role from interim CEO and board member Vincent Miles.
The new CEO previously served as Head of Cleveland Clinic Laboratories (CCL) and chief operating officer of the Pathology and Laboratory Medicine Institute. Before that, he worked as the Medical Scientist for the Novartis Institutes for Biomedical Research Drug Discovery Incubator. McManus earned a Ph.D. from the University of Pennsylvania School of Medicine, an MBA from Boston College and a bachelor's degree from the College of the Holy Cross.
PrimeraDx develops a proprietary nucleic acid analysis system, STAR (Scalable Target Amplification Routine), invented by Vladimir Slepnev, Primera’s chief scientific officer and co-founder. The company closed a $20 million Series C round of financing, led by new investor CHL Medical Partners, in September 2009.
Primera was spun off from Providence, R.I.-based life sciences company Sention Inc., and started out based in Providence before moving to Mansfield in 2006.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
